EGFR and non-small cell lung carcinoma: A recent retrospective study analyzed the clinical efficacy of EGFR-TKI plus bevacizumab (VEGF inhibitor) versus EGRK-TKI alone in advanced NSCLC patients with EFGR mutations and BIM deletion and found that the addition of bevacizumab resulted in significantly higher ORR, longer PFS, and a tendency toward a favorable OS [56].